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DRUG POINTS
Erythrodertna after clodronate
treatment
Drs I PAJUS, P ILSTANG, F ILoTr,
and Prof A DRYLL (H6pital Lari-
boisiere, 75010 Paris, France) write:
The bisphosphonates, including clo-
dronate, are powerful inhibitors of
bone resorption. Until now clinical
studies of clodronate have shown
good tolerability and safety, with no
reports of any cutaneous side effects.
We report here erythroderma with
lesions of the mucous membranes
after oral and intravenous clodronate
administration.
A 70 year old man was admitted in
June 1991 for vertebral pain and
hypercalcaemia which led to the diag-
nosis of stage IIIA multiple myeloma.
A single infusion of 300 mg of clo-
dronate was given, and a course of
vincristine, melphalan, cyclophos-
phamide, and prednisolone every
four weeks was started. Amiodarone
(200 mg/day) was prescribed for a
tachycardia.
Two weeks later he noticed a rash,
which lasted three days. On 12 June
1992 he was admitted for the 13th
course of chemotherapy. At the same
time he received a second infusion
of intravenous clodronate 300 mg
and was started on oral clodronate
800 mg daily. On 29 June he
developed a generalised erythema-
tous macular and papular rash, with-
out pruritus, and a fever of 40°C. He
also had lesions of the buccal and
genital mucous membranes and a
punctate keratitis. On 1 July his
clinical state was unchanged. He
received intramuscular betametha-
sone and oral HI antihistamines. The
oral clodronate was stopped.
The white blood cell count was
normal, without eosinophilia; he
had no infection; viral serology
gave negative results. A histological
examination of the skin showed
epidermal changes, with a dermal
lymphohistiocytic and eosinophilic
infiltration strongly suggestive of
toxiderma.
Within a few days the eruption
gradually regressed without residual
pigmentation. Other drugs were
continued without reappearance of
the rash.
The delay in the appearance of the
rash after the first administration of
clodronate, the relapse following its
reintroduction, and the regression
after the end of clodronate treatment
all support clodronate as the cause of
the erythroderma, as do the patho-
logical features and the fact that no
other drug was introduced.' The
cutaneous side effects of bisphospho-
nates are uncommon. They have
been reported with pamidronate2 3
and tiludronate,4 but only rarely
during 10 years' prescription of eti-
dronate. No cutaneous reactions to
clodronate have been reported to
the French National Centre for
Pharmacovigilance or the drug
company.'
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Agranulocytosis associated
with cephalosporin
Drs C H Hui and L C CHAN (Depart-
ment of Pathology, University of
Hong Kong, Queen Mary Hospital)
write: A healthy 15 year old boy was
given cefuroxime (Zinacef) 750 mg
intravenously every eight hours for
fever associated with pneumonia
which developed after orthopaedic
surgery. As neither fever nor pneu-
monia improved cefuroxime was
discontinued after 17 days and cef-
tazidime substituted at a dose of 1 g
intravenously twice a day. Twenty
four hours later the patient had no
fever and a full blood count showed
haemoglobin 132 g/l, white cell count
6 30x109/1 with neutrophils 3 75x
109/1, and platelet count 379x109/l.
Coagulation and renal and liver
function were normal.
On the seventh day of ceftazidime
administration fever recurred, and
isolated leucopenia (white cell count
1 90 x 109/l) associated with agranu-
locytosis (white cell differential
(x 109/l) 0 neutrophils, 1 25 lympho-
cytes, 0 61 monocytes, 0 04 eosino-
phils) was noted. Ceftazidime was
stopped and a bone marrow aspirate
the next day showed a normocellular
marrow with strikingly reduced
myelopoiesis. Bacterial cultures and
viral screen were negative. In view
of the agranulocytosis, subcutaneous
injection of granulocyte macrophage
colony stimulating factor 1 phial
daily was started. Both total white
cell (4 8 x 19/1) and neutrophil count
(22x 109/l) recovered within 24
hours. Altogether two doses of granu-
locyte macrophage colony stimu-
lating factor were given, and the
white cell counts remained sustained
since then.
Transient leucopenia is recognised
after cephalosporin administration
and is more likely to occur after high
doses and prolonged therapy.'-4 In
our case we could not determine
whether the agranulocytosis was due
to ceftazidime or cefuroxime (or
both). The prompt recovery may
have been due to the cessation of
cephalosporin treatment rather than
the granulocyte macrophage colony
stimulating factor treatment. We
suggest that patients should have
regular full blood count while receiv-
ing cephalosporins.
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Cyclosporin induced colitis
Drs J R C BOWEN and S SAHi (BMH
Rinteln, BFPO 29, Germany) write:
A 40 year old woman presented with
a two year history of weight loss,
lethargy, and pruritus. Biochemistry
tests showed raised alkaline phos-
phatase concentrations and a high
titre of antimitochondrial antibody.
Liver biopsy confirmed a clinical
diagnosis of primary biliary cirrhosis.
Cholestyramine was started for her
pruritus, to which cyclosporin was
added. Serum concentrations of
cyclosporin on a dose of 150 mg daily
were 99 2 nmol/l (124 ng/ml).
Five months later she complained
of abdominal pain with increased
bowel frequency, loose motions, and
mucus per rectum. Investigations
showed peripheral blood eosino-
philia, but stool microscopy and
culture gave negative results, as
did upper gastrointestinal endoscopy
and a histological examination of the
lower duodenun. Colonoscopy, how-
ever, showed widespread colitis,
confirmed histologically as a "non-
specific colitis."
Cyclosporin was stopped, and all
gastrointestinal symptoms resolved
within one week. Colonoscopy
shortly afterwards showed improved
macroscopic and histological ap-
pearances.
With the patient's permission she
was rechallenged with cyclosporin.
This resulted in a recrudescence
of her symptoms within four days.
Repeat colonoscopy showed a patchy
colitis, which was worse than on her
previous examination. Histologically
the inflammation was comparable in
specimens from the second examina-
tion, but this might have been due to
the necessarily brief rechallenge.
Colitis associated with cyclosporin
A has been reported on two pre-
vious occasions.'2 In the first of
these, however, drug concentrations
were in the toxic range exceeding
640 nmol/l (800 ng/ml), and in the
second case typical ulcerative colitis
started while a patient was receiving
cyclosporin and continued despite its
withdrawal. To our knowledge this is
the first reported case of a reversible
cyclosporin induced colitis occurring
in a patient with cyclosporin concen-
trations in the therapeutic range.
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Lancet 1991;338:389.
Transcutaneous overdose of
terbutaline
Drs G J INGRAMS (Kidderminster
General Hospital, Kidderminster
DYI1 6RJ) and F B MORGAN
(Aylmer Lodge Surgery, Kidder-
minster) write: A 15 year old mildly
asthmatic boy was admitted with
tachycardia (rate 130 beats/min),
a loud systolic murmur at his left
sternal edge, and tremor. Feeling
slight tightness of his chest after
playing football, he had inhaled two
puffs (500 ,ug) of terbutaline. He
then discovered that spraying the
aerosol on to a patch of itching tinea
crutis in his groin produced cooling
relief and administered at least
eight puffs. Ten minutes later he
developed fast, regular palpitations
and an uncomfortable feeling in his
chest and therefore inhaled a further
two puffs.
Investigations showed hypo-
kalaemia (2 7 mmolIl), hypergly-
caemia (14 8 mmol/l), normal arterial
blood gas values, and sinus tachy-
cardia. A subsequent echocardio-
gram was normal. His signs and
symptoms were consistent with
terbutaline overdose and settled over
24 hours without specific treatment.
The total inhaled dose (1 mg) was
insufficient to cause such a clinical
picture, but the total dose sprayed on
to the skin (2 mg) was four times
greater than the maximum dose for
subcutaneous injection (500 pug).
Although transcutaneous absorp-
tion has not been documented for
P2 agonists, the absorption of ter-
butaline is increased across damaged
tracheal epithelium in vitro.' Over-
dose of FP2 agonists is associated
with hypokalaemia,' which can cause
sudden death.'4 Transcutaneous
absorption should be considered,
particularly when nebulising atopic
children with facial eczema and those
with facial dermatitis.5
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